/

Empresas

Da

No verificado

Daiichi Sankyo

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

93 Comunicados de prensa

Ver todos los comunicados de prensa

28/05/2026

Eventos

Industria

Ciencia

Biotecnología

Medicina - Varios

Salud

Farmacéutica

Sanidad

Oncología

Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO

Fuente

Editor

1.00

0

22/05/2026

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Higiene alimentaria

Medicina - Varios

Industria

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

Fuente

Editor

1.00

0

22/05/2026

Oncología

Salud

Biotecnología

Medicina - Varios

Farmacéutica

Mercado laboral

Industria

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors

Fuente

Editor

1.00

0

15/05/2026

Industria

Oncología

Salud

Higiene alimentaria

Medicina - Varios

Farmacéutica

Biotecnología

Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer

Fuente

Editor

1.00

0

11/05/2026

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation

Fuente

Editor

1.00

0

13/04/2026

Mercado laboral

Industria

Ciencia

Higiene alimentaria

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Sanidad

Oncología

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

Fuente

Editor

1.00

0

09/03/2026

Industria

Ciencia

Higiene alimentaria

Medicina - Varios

Biotecnología

Sanidad

Farmacéutica

Salud

Oncología

ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

Fuente

Editor

1.00

0

20/02/2026

Mercado laboral

Oncología

Salud

Sanidad

Ciencia

Farmacéutica

Biotecnología

Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D

Fuente

Editor

1.00

0

19/02/2026

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

Fuente

Editor

1.00

0

04/02/2026

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0